Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants
- 4 July 2023
- journal article
- research article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (6) , 1700-1705.e4
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threatJournal of Hepatology, 2018
- Cost-effectiveness of hepatitis C–positive donor kidney transplantation for hepatitis C–negative recipients with concomitant direct-acting antiviral therapyAmerican Journal of Transplantation, 2018
- Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort StudyOpen Forum Infectious Diseases, 2018
- Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United StatesJournal of General Internal Medicine, 2018
- The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United StatesAnnals of Internal Medicine, 2018
- Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected RecipientsAnnals of Internal Medicine, 2018
- Trial of Transplantation of HCV-Infected Kidneys into Uninfected RecipientsNew England Journal of Medicine, 2017
- Transplanting Hepatitis C–Positive KidneysNew England Journal of Medicine, 2015
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- Underutilization of Hepatitis C-Positive Kidneys for Hepatitis C-Positive RecipientsAmerican Journal of Transplantation, 2010